1. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148–1159.
Article
2. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008; 49:17N–21N. 37N
3. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2:683–693.
Article
4. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41:661–681.
5. Jadvar H. FDG PET in Prostate Cancer. PET clinics. 2009; 4:155–161.
Article
6. Lebret T, Mejean A. [Rare locations of metastases from prostate cancer]. Prog Urol. 2008; 18:S357–S364.
7. Venara A, Thibaudeau E, Lebdai S, Mucci S, Ridereau-Zins C, Azzouzi R, et al. Rectal metastasis of prostate cancer: about a case. J Clin med res. 2010; 2:137–139.
Article
8. Bowrey DJ, Otter MI, Billings PJ. Rectal infiltration by prostatic adenocarcinoma: report on six patients and review of the literature. Ann R Coll Surg Engl. 2003; 85:382–385.
Article
9. Liu L, Devine P, Einhorn E, Kao GD. Incidental finding of an isolated prostate cancer metastasis in an inguinal hernial sac. J Urol. 2000; 164:457–458.
Article
10. Kanamaru H, Oyama N, Akino H, Okada K. [Evaluation of prostate cancer using FDG-PET]. Hinyokika kiyo. 2000; 46:851–853.
11. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001; 57:108–111.
Article
12. Jadvar H, Pinski JK, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncology reports. 2003; 10:1485–1488.
Article
13. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998; 58:3009–3014.
14. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999; 29:623–629.
Article
15. Sanz G, Robles JE, Gimenez M, Arocena J, Sánchez D, Rodriguez-Rubio F, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 1999; 84:1028–1031.
Article